

Best Available Copy

Complete Listing of the Claims

Claims 1-40 (cancelled)

41. (previously presented) A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of *N*-(2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl)-(R)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine or a pharmaceutically-acceptable salt thereof.

42. (previously presented) The pharmaceutical composition of Claim 41, wherein the composition is formulated for administration by inhalation.

43. (previously presented) The pharmaceutical composition of Claim 41 wherein the composition further comprises a therapeutically effective amount of a steroidal anti-inflammatory agent.

44. (previously presented) The pharmaceutical composition of Claim 43, wherein the composition is formulated for administration by inhalation.

45. (previously presented) The pharmaceutical composition of Claim 41, wherein the composition further comprises a therapeutically effective amount of one or more therapeutic agents selected from the group consisting of a steroidal anti-inflammatory agent, a muscarinic receptor antagonist agent, a phosphodiesterase inhibitor agent, an immunoglobulin antibody, a leukotriene antagonist agent, a cytokine antagonist agent, a protease inhibitor, cromolyn sodium, nedocromil sodium, and sodium cromoglycate.

46. (previously presented) A method of treating a disease or condition in a mammal associated with β_2 adrenergic receptor activity, the method comprising administering to the mammal, a therapeutically effective amount of a pharmaceutical composition of Claim 41.

Best Available Copy

47. (previously presented) The method of Claim 46 wherein the disease or condition is a pulmonary disease.
48. (previously presented) The method of Claim 47 wherein the pulmonary disease is asthma or chronic obstructive pulmonary disease.
49. (previously presented) The method of Claim 46 wherein the disease or condition is selected from the group consisting of pre-term labor, neurological disorders, cardiac disorders, and inflammation.
50. (previously presented) The method of Claim 46 further comprising administering a therapeutically effective amount of a steroidal anti-inflammatory agent.
51. (previously presented) The method of Claim 46 further comprising administering a therapeutically effective amount of one or more therapeutic agents selected from the group consisting of a steroidal anti-inflammatory agent, a muscarinic receptor antagonist agent, a phosphodiesterase inhibitor agent, an immunoglobulin antibody, a leukotriene antagonist agent, a cytokine antagonist agent, a protease inhibitor, cromolyn sodium, nedocromil sodium, and sodium cromoglycate.